Back to ALCView Full LandscapeView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
3 competitors in Open-angle Glaucoma
ALCOX.PANCX 470 0.1%
Phase 3ALCOX.PANCX 470 0.065% (initial phase of trial)
Phase 3ABBVBimatoprost (SR)
Phase 3Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA11/27/2001
Travatan
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Ofloxacin otic solutionPhase 3
Acute Otitis Media
Difluprednate 0.05% ophthalmic emulsionPhase 3
Endogenous Anterior Uveitis
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Phase 3
Allergic Conjunctivitis
AL-4943A ophthalmic solutionPhase 3
Allergic Conjunctivitis
Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solutionPhase 3
Glaucoma, Open-angle
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts